Bicycle Therapeutics(BCYC) - 2025 Q4 - Annual Results

Financial Performance - Cash and cash equivalents were $628.1 million as of December 31, 2025, down from $879.5 million as of December 31, 2024, primarily due to cash used in operations[5] - Net loss for Q4 2025 was $20.2 million, or $(0.29) per share, compared to a net loss of $51.9 million, or $(0.75) per share, in Q4 2024[8] - The net loss for Q4 2025 was $20.154 million, compared to a net loss of $51.854 million in Q4 2024, reflecting a reduction in losses of approximately 61%[12] - The company reported a net loss per share of $0.29 for Q4 2025, an improvement from a loss of $0.75 per share in Q4 2024[12] - Total operating expenses for Q4 2025 were $72.663 million, slightly higher than $71.371 million in Q4 2024, indicating a year-over-year increase of about 1.8%[12] Research and Development - R&D expenses for Q4 2025 were $51.8 million, compared to $49.8 million in Q4 2024, with annual R&D expenses increasing to $240.3 million from $173.0 million[8] - Research and development expenses for the year ended December 31, 2025, totaled $240.283 million, up from $172.966 million in 2024, marking an increase of about 39%[12] - Bicycle Therapeutics plans to convert the ongoing Duravelo-2 trial to a randomized Phase 2 study and deprioritize the internal development of zelenectide[2] - The Phase 2/3 Duravelo-2 trial demonstrated an overall response rate (ORR) of 65% assessed by physicians and 58% confirmed by blinded independent central review (BICR) at the 27-week cutoff[3] - The company expects to present initial dose selection data from the Duravelo-2 trial at an upcoming scientific conference[3] - The first company-sponsored radioligand clinical trial for BT1702 is expected to initiate in 2027, with additional EphA2 human imaging data anticipated in the first half of 2026[4] - The company is initiating new clinical trials for BT1702, an MT1-MMP targeting BRC, and is progressing with trials for BT5528 and BT7480[10] Collaboration and Revenue - Collaboration revenue increased to $48.0 million for Q4 2025 and $72.6 million for the year, compared to $3.7 million and $35.3 million in the respective periods of 2024[8] - Collaboration revenue for Q4 2025 was $47.955 million, a significant increase from $3.708 million in Q4 2024, representing a growth of approximately 1,292%[12] - Bicycle Therapeutics expects to leverage its agreements with NDA and SpectronRx to support the discovery and development of a portfolio of BRCs[10] Strategic Initiatives - The company anticipates annual operational savings of approximately 50% from a proposed workforce reduction of about 30%[3] - Bicycle Therapeutics is focusing on strategic reprioritization to potentially extend its financial runway and reduce expenditures through a proposed workforce reduction[10] - Bicycle Therapeutics has established a 15-year contract with the UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium to support its radiopharmaceutical pipeline[3] - The company anticipates multiple regulatory pathways for its product zelenectide pevedotin in mUC, indicating potential for future commercialization[10] Assets - The total assets as of December 31, 2025, were reported at $717.597 million, compared to $686.868 million as of December 31, 2024[14]